Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus

Journal of Pediatrics

Volumn 136, Issue 2, 2000, Pages 243-247

  Lehman, Thomas J A ^a,b   Onel, Karen ^a  

^a Department of Obstetrics Gynecology   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANISETRON; MESNA; METHYLPREDNISOLONE; ONDANSETRON; PREDNISONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0033913042     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(00)70109-0     Document Type: Article

References (23)

1. 1. Lehman TJ. A practical guide to systemic lupus erythematosus. Pediatr Clin North Am 1995;42:1223-38.
2. 2. Lehman TJ. Long-term outcome of systemic lupus erythematosus in childhood. What is the prognosis? Rheum Dis Clin North Am 1991;17:921-30.
3. 3. Fish AJ, Blau EB, Westberg NG, Burke BA, Vernier RL, Michael AF. Systemic lupus erythematosus within the first two decades of life. Am J Med 1977;62:99-117.
4. 4. Glidden RS, Mantzouranis EC, Borel Y. Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 1983;29: 196-210.
5. 5. Norris DG, Colon AR, Stickler GB. Systemic lupus erythematosus in children: the complex problems of diagnosis and treatment encountered in 101 such patients at the Mayo Clinic. Clin Pediatr (Phila) 1977;16:774-8.
6. 6. Lehman TJ, Sherry DD, Wagner L, McCurdy DK, Emery H, Magilavy DB, et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989;114:1055-60.
7. 7. Balow JE, Austin HA, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984;311:491-6.
8. 8. Austin HA, Klippel JH, Balow JE, le-Riche N-G, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614-9.
9. 9. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57.
10. 10. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741-5.
11. 11. Tan E, Cohen MA, Fries JF, Masi AT, McShane Dj, Rothfield N, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1995;25: 1271-7.
12. 12. Steinberg AD, Gourley M. Cyclophosphamide in lupus nephritis. J Rheumatol 1995;22:1812-5.
13. 13. Lehman TJ, Mouradian J. Systemic lupus erythematosus. In: Barratt TM, Avner ED, Harmon WE, editors. Pediatric nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 1999. p. 793-810.
14. 14. Lehman TJ, McCurdy DK, Bernstein BH, King KK, Hanson V. Systemic lupus erythematosus in the first decade of life. Pediatrics 1989;83:235-9.
15. 15. Hahn TJ, Hahn BH. Osteopenia in patients with rheumatic disease: principles of diagnosis and therapy. Semin Arthritis Rheum 1976;6:165-88.
16. 16. Homcy CJ, Liberthson RR, Fallon JT, Gross S, Miller LM. Ischemic heart disease in systemic lupus erythematosus in the young patient: report of six cases. Am J Cardiol 1982;49:478-84.
17. 17. Rees L, Chantler C. Growth and endocrine function in children receiving long-term steroid therapy for renal disease. Acta Paediatr Scand 1990;366: S93-S96.
18. 18. Sergent JS, Lockshin MD, Klempner MS, Lipsky BA. Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis. Am J Med 1975;58:644-54.
19. 19. Wolkowitz OM, Reus VI, Weingartner H, Thompson K, Breier A, Doran A, et al. Cognitive effects of corticosteroids. Am J Psychiatry 1990;147:1297-303.
20. 20. Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994;42:71-8.
21. 21. Langevitz P, Klein L, Pras M, Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol 1992;28:157-8.
22. 22. Belmont HM, Storch M, Buyon J, Abramson S. New York University/ Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995; 4:104-8.
23. 23. Pablos JL, Gutierrez-Millet V, Gomez-Reino JJ. Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol 1994;23:142-4.